SCHEMBL2189673

SCHEMBL2189673

CCOC(=O)c1nn(C)c2c1COc1cc(F)ccc1-2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.55
POLB P06746 2/20 0.55
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
NR1H4 Q96RI1 5/20 0.42
GABRG2 P18507 3/20 0.41
GABRB3 P28472 3/20 0.41
GABRA5 P31644 3/20 0.41
GABRA2 P47869 2/20 0.41
GABRB2 P47870 2/20 0.41
MEN1 O00255 1/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
GABRA1 P14867 1/20 0.41
TSHR P16473 1/20 0.41
GABRB1 P18505 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2549040 0.92 TP53 (0.55) TP53POLBMAPTALDH1A1KDM4E
SCHEMBL2173426 0.84 TP53 (0.73) TP53POLBMAPTALDH1A1KDM4E
SCHEMBL2171176 0.84 MAPT (0.46) TP53POLBMAPTNR1H4PIK3CD
SCHEMBL17978169 0.82 TP53 (0.59) TP53POLBMAPTALDH1A1KDM4E
SCHEMBL2542694 0.81 TP53 (0.58) TP53POLBMAPTALDH1A1KDM4E
SCHEMBL19810692 0.80 TP53 (0.55) TP53POLBMAPTNR1H4GABRG2
SCHEMBL22299813 0.79 MAPT (0.54) TP53POLBMAPTALDH1A1KDM4E
SCHEMBL14532847 0.77 ALDH1A1 (0.55) TP53POLBALDH1A1KDM4EHPGD
SCHEMBL7918 0.77 MAPT (0.56) TP53MAPTLMNA
SCHEMBL2171950 0.77 TP53 (0.46) TP53POLBMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2011-10-27 US disclosed
EP-2346832-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS Glaxo Group Limited (GB) 2011-07-27 EP disclosed
WO-2010049366-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263588-A1 TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS GRM5, GRM1, GRM3 TP53 4565/4885POLB 4360/4885MAPT 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.